Rate My Professor Thomas Giordano

Thomas Peter Giordano, MD, MPH, is Professor in the Department of Medicine, Section of Infectious Diseases, at Baylor College of Medicine, serving as Chief of the Section of Infectious Diseases, Director of the Texas Developmental Center for AIDS Research (TX D-CFAR), and MD Anderson Foundation Chair. He also holds the position of Program Chief, Clinical Effectiveness and Population Health Program, at the Michael E. DeBakey VA Medical Center's Center for Innovations in Quality, Effectiveness and Safety. Previously, from 2004 to 2021, he was Medical Director of HIV Services for Harris Health System and the Thomas Street Health Center, one of the largest HIV clinics in the United States. Giordano is board certified in Internal Medicine and Infectious Diseases by the American Board of Internal Medicine.

Giordano received a BS in Biology and BA in Humanities from John Carroll University in 1988, an MA in History of Art from Cornell University in 1992, an MD from Johns Hopkins University School of Medicine in 1996, completed Internal Medicine residency at the Hospital of the University of Pennsylvania in 1999, Infectious Diseases fellowship at Baylor College of Medicine in 2002, and an MPH in Disease Control from the University of Texas Health Science Center School of Public Health in 2004. His research focuses on HIV testing, adherence to antiretroviral therapy, and retention in HIV care, with particular emphasis on minority and disadvantaged populations. Nationally recognized as an authority in adherence and retention in HIV care research, he has published more than 180 peer-reviewed manuscripts and served as principal investigator on 15 grants from agencies including NIH, CDC, HRSA, and VA. Notable funding includes TX D-CFAR (P30AI161943, 2021-2026), THRIVE (R34MH122294, 2020-2023), and Wastewater Sampling: A New Tool to Accelerate Ending the HIV Epidemic (R01DA059394, 2023-2028). Key publications encompass 'Retention in care: a challenge to survival with HIV infection' (Clin Infect Dis, 2007), 'Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus' (JAMA, 2007), and 'Accessing antiretroviral therapy following release from prison' (JAMA, 2009). He is a Fellow of the Infectious Diseases Society of America and has contributed to major panels, including the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (2014-2023), NIH Behavioral and Social Consequences of HIV/AIDS Study Section (2012-2018), and US FDA Antiviral Drugs Advisory Committee (2011-2014).